Company profilePharmaceutical#577 of 1,318 in Pakistan✓ No DRAP alerts

MEEZAB INTERNATIONAL

Pharmaceutical company · 21 brands · 29 molecules

Ranked #59 of 62 companies in Drugs For Obstructive Airway Diseases, Systemic

21 registered products 12 pharmaceutical brands 29 distinct molecules 0 DRAP alerts

Company overview

21
registered products
12
pharmaceutical brands
29
distinct molecules
5
therapeutic classes
0
DRAP alerts

MEEZAB INTERNATIONAL is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 21 product registrations across 29 distinct molecules. Its portfolio is concentrated in Drugs For Obstructive Airway Diseases, Systemic and Antidepressants. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Enalapril1 brand
Artemether1 brand
Artemether.......................80Mg1 brand
Lumefantrine ...... 20 &1 brand
Cephradine1 brand
Nalbuphine1 brand

Therapeutic classes

Drugs For Obstructive Airway Diseases, Systemic · 1Antidepressants · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Other Beta-Lactam, Cephalosporins & Penems · 1Quinolone Antibacterials · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official5 products · Rs 509.05 – Rs 977.36
DVAGO1 products · Rs 334.3 – Rs 334.3
Median across source: Rs 660.9

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for MEEZAB

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.